Skip to main content
Premium Trial:

Request an Annual Quote

Aclara and Stanford Extend eTag Contract

NEW YORK, June 18 -- Aclara BioSciences announced today the extension of a services and supply agreement with Stanford University for use in a new proteomics center.


The Mountain View, Calif.-based company will supply the Stanford University Medical Center with access to its eTag assay system technology, custom services, reagents, software, and support. The university will use the system for proteomics studies in the area of autoimmune disease.


Financial details were not disclosed.


Using funding from a seven-year, $14.6 million contract from the National Heart Lung and Blood Institute, Stanford's Center for Clinical Immunology will establish a proteomics center to study autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis.


ACLARA's eTag technology is used in the analysis of genes and proteins.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.